Biohaven Pharmaceutical Holding Co Ltd
Biohaven Pharmaceutical — Corporate Update (February 2020)
17 slides from Biohaven Pharmaceutical's corporate update, Feb 28, 2020

Slide 1: Nurtec ODT Investor Webcast
© 2018 Biohaven Pharmaceuticals. All rights reserved. Nurtec™ ODT Investor Webcast FEBRUARY 28, 2020NYSE: BHVN

Slide 2: Now FDA Approved
Now FDA Approved 2 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

Slide 3: Nurtec ODT: One Dose, Anytime, Anywhere
Sustained response up to 48 hours. Half-life of 11 hours. One Dose. Anytime. Anywhere. No titration needed. Quick-dissolve ODT can start working in minutes IMPORTANT SAFETY INFORMATION Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions: If a serious

Slide 4: Now FDA Approved 4 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES
Now FDA Approved 4 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

Slide 5: Migraine Significantly Impairs Patients' Lives
Migraine Significantly Impairs Patient’s Lives Migraine affects ~15% of the US population1 with prevalence highest during peak employment years (25–55 years of age)3 1 in 5 women2 20,000 per 100,000 women 1 in 16 men2 6,250 per 100,000 men • • Chronic neurological disease characterized by disabling

Slide 6: Migraine Attacks: A Leading Cause of Economic Burden
Migraine Attacks: A Leading Cause of Economic Burden in US costs for migraine in the US are estimated at $27 BILLION1 Annual total ~25% OF ER VISITS FOR MIGRAINE were followed by a second ER visit for headache in <6 months2 In a study of over 850,000 patients with migraine, patients with 2 or more m

Slide 7: Now FDA Approved 7 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES
Now FDA Approved 7 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

Slide 8: FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 8
FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 8

Slide 9: One dose rimegepant 75 mg ODT delivered superior efficacy vs placebo across 21 endpoints
One dose rimegepant 75 mg ODT delivered superior efficacy vs placebo across a broad-spectrum of 21 hierarchically tested endpoints1 sk Freedom from MBS,2 hrs 35.1 26.8 • Ability to function normally, 2 hrs Sustained pain relief,2-24 hrs 38.1 47.8 25.8 27.7 No rescue medication within 24 hrs 70.8 16.

Slide 10: No individual adverse event had an incidence greater than 2%
2% No individual AE had an incidence greater than 2%1;3* IMPORTANT SAFETY INFORMATION Contraindications: Hypersensitivity to Nurtec ODT or any of its components. Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious

Slide 11: Now FDA Approved 11 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES
Now FDA Approved 11 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

Slide 12: ICER report on cost effectiveness of rimegepant
“In our analysis of the cost effectiveness…we found that for patients not tolerated, or cost effective at for whom triptans are not effective, are contraindicated…rimegepant…[is] commonly used thresholds.” 25th ICER Report Feb 2020, Page ES18 Atlas S, Touchette D, Agboola F, Lee T, Chapman R, Pearso

Slide 13: Nurtec ODT blister pack instructions
Now FDA PEEL....HERE Approved INSTRUCTIONS PEEL....HERE PEEL.A.HERE btohoven .. PEEL....HERE btohoven pharmaceuticals NURTECTN OOT {rimegepant) orally disintegrating tablets 75me Lot Exp; btohoven pharmoc90tic:ats NURTECTN OOT {rimegepantl orally disintegrating tablets 75mg Lot Exp; biOhov.n pharmac

Slide 14: Now FDA Approved 14 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES
Now FDA Approved 14 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

Slide 15: ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES
ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

Slide 16: Now FDA Approved 16 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES
Now FDA Approved 16 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES

Slide 17: Nurtec ODT blister pack instructions
Now FDA PEEL....HERE Approved INSTRUCTIONS PEEL....HERE PEEL.A.HERE btohoven .. PEEL....HERE btohoven pharmaceuticals NURTECTN OOT {rimegepant) orally disintegrating tablets 75me Lot Exp; btohoven pharmoc90tic:ats NURTECTN OOT {rimegepantl orally disintegrating tablets 75mg Lot Exp; biOhov.n pharmac
Source: SEC EDGAR · 8-K filed Feb 28, 2020
More decks from Biohaven Pharmaceutical Holding Co Ltd
Investor Presentation (September 2021)89 slides · Sep 27, 2021
Leerink Fireside Chat June 202123 slides · Jun 29, 2021
Investor Presentation (June 2020)76 slides · Jun 2, 2020
Technical Presentation (March 2020)8 slides · Mar 31, 2020
Investor Presentation (January 2020)71 slides · Jan 13, 2020
Investor Presentation (October 2019)67 slides · Oct 3, 2019